Ksilink is dedicated to foster patient-based therapeutic approaches including personalized strategies as a means to stratify potential targeted therapies in a clinically relevant timeframe.
As part of an international team, Ksilink contributed to the development of a patient-derived glioblastoma organoid (PD-GBO) platform for preclinical identification of new drugs against defined morphological glioblastoma features. In a proof-of concept study applied it to four patient tumors, the team demonstrated the utility of the platform as an empirical methodology to preclinically discover potentially effective treatments, producing actionable results within a period of about two weeks.
More details can be found in our recent publication (Ratliff, M.; Kim, H.; Qi, H.; Kim, M.; Ku, B.; Azorin, D.D.; Hausmann, D.; Khajuria, R.K.; Patel, A.; Maier, E.; Cousin, L.; Ogier, A.; Sahm, F.; Etminan, N.; Bunse, L.; Winkler, F.; El-Khoury, V.; Platten, M.; Kwon, Y.-J. Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma. Int. J. Mol. Sci. 2022, 23, 6572. https://doi.org/10.3390/ijms23126572).